The emergence of cancer immunotherapy has already shown some remarkable results for the treatment of solid tumors. As good as this is, patients seem to lack the ability to respond to immune checkpoint inhibitors, thus demonstrating a primary resistance to immunotherapy.
By reducing tumor hypoxia (low oxygen) within solid tumors. hyperbaric oxygen therapy (HBOT) can help reinvigorate anti-cancer immunity.
In this study, HBOT was able to stimulate a suppressed immune system and help PD-1 Ab trigger robust cytotoxic T lymphocytes and long-lasting immunological memory to inhibit tumor relapses.
Emerging research suggests that T cell-directed checkpoint antibodies such as anti-programmed cell death protein-1 (PD-1) or programmed death-ligand-1 (PD-L1) can impact innate immunity by both direct and indirect pathways, which may ultimately shape clinical efficacy. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to “trick” the immune system, and avoid being attacked as foreign, harmful substances..
Hyperbaric Oxygen Boosts PD-1 Antibody Delivery — “The results illustrate that HBO bolsters antitumor efficacy of PD-1 Ab, and the HBO-PD-1 Ab combination is a promising stroma-rich solid tumors’ treatment in the clinic” <view study>